Intrathecally Administered Natural Human Fibroblast Interferon Reduces Exacerbations of Multiple Sclerosis: Results of a Multicenter, Double-blinded Study

Archives of Neurology

Volumn 44, Issue 6, 1987, Pages 589-595

  Jacobs, Lawrence ^a,b   Salazar, Andres M ^c,d   Herndon, Robert ^e   Reese, Peter A ^f   Freeman, Arnold ^f   Jozefowicz, Ralph ^e   Cuetter, Albert ^c   Husain, Farhat ^c   Smith, William A ^c   Ekes, Roslyn ^a   O'malley, Judith A ^b,f  

^a New York Dent Neurologic Institute   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CORTICOTROPIN; INDOMETACIN; PLACEBO;

ADVERSE DRUG REACTION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG THERAPY; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INFLUENZA; INTOXICATION; INTRATHECAL DRUG ADMINISTRATION; LETHARGY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NEUROTOXICITY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY; VOMITING;

ADULT; DOUBLE-BLIND METHOD; HUMANS; INDOMETHACIN; INJECTIONS, SPINAL; INTERFERON TYPE I; MULTIPLE SCLEROSIS; RANDOM ALLOCATION;

EID: 0023217310     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.1987.00520180013008     Document Type: Article

References (43)

1. Jacobs L, O'Malley J, Freeman A, et al: Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981;214:1026-1028.
2. Jacobs L, O'Malley J, Freeman A, et al: Intrathecal interferon in multiple sclerosis. Arch Neurol 1982;39:609-615.
3. Stewart WE II: The Interferon System. New York, Springer-Verlag NY Inc, 1979.
4. Dunnick JK, Galasso GJ: Clinical trials with exogenous interferon: Summary of a meeting. J Infect Dis 1979;139:109-123.
5. Cook D, Dowling PC: Multiple sclerosis and viruses: An overview. Neurology 1980;20:80-91.
6. Leibowitz S: The immunology of multiple sclerosis, in Hallpike JF, Adams CWM, Tourtellotte WW (eds): Multiple Sclerosis. Baltimore, Williams & Wilkins, 1983, pp 379-412.
7. Ter Meulen V, Stephenson JR: The possible role of viral infections in multiple sclerosis and other related demyelinating diseases, in Hallpike JF, Adams CWM, Tourtellotte WW (eds): Multiple Sclerosis. Baltimore, Williams & Wilkins, 1983, pp 241-274.
8. Salazar AM, Gibbs CJ, Gajudsek DC, et al: Clinical use of interferons: Central nervous system disorders, in Came P, Carter WA (eds): Handbook of Experimental Pharmacology. New York, Springer-Verlag NY Inc, 1983, vol 71, pp 472-497.
9. Emodi G, Just M, Hernandez R, et al: Circulating interferon in man after administration of exogenous human leukocyte interferon. JNCI 1975;54:1045-1049.
10. De Clercq E, Edy VG, de Vlieger H, et al: Intrathecal administration of interferon in neonatal herpes. J Pediatr 1975;86:736-739.
11. Habif DV, Liptin R, Cantell K: Interferon crosses the blood-cerebrospinal fluid barrier in monkeys. Proc Soc Exp Biol Med 1975;149:287-298.
12. Hilfenhaus J, Weinman E, Major M, et al: Administration of human interferon to rabies virus-infected monkeys after exposure. J Infect Dis 1977;135:846-849.
13. Misset JL, Mathe G, Horoszewicz JS: Intrathecal interferon in meningeal leukemia. N Engl J Med 1981;304:1544.
14. Prange H, Wismann H: Intrathecal use of interferon in encephalitis. N Engl J Med 1981;305:1283-1284.
15. Smith RA, Norris F, Palmer D, et al: Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 1985;1:85-88.
16. Obbens EAMT, Feum LG, Leavens ME, et al: Interferon in the treatment of intracranial malignancies: A pilot study. Neurology 1984;34(suppl 1):232.
17. Slatkin NE, Jaeckle KA, Lukes SA, et al: Treatment of leptomeningeal gliomatosis with human leukocyte interferon: Results in two patients. Neurology 1984;34(suppl 1):151.
18. Mora JS, Munsat TL, Kao KP, et al: Intrathecal administration of natural human interferon alpha in amyotrophic lateral sclerosis. Neurology 1986;36:1137-1140.
19. Jacobs L, O'Malley JA, Freeman A, et al: Intrathecal interferon as treatment of multiple sclerosis: A planned multicenter study. Arch Neurol 1983;40:683-686.
20. Schumacher GA, Bebe G, Kibler RF, et al: Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;122:552-562.
21. McDonald WI: What is multiple sclerosis? Clinical criteria for diagnosis, in Davison AN, Humphrey JH, Liversedge LA, et al (eds): Multiple Sclerosis Research. New York, Elsevier Science Publishing Co Inc, 1975, p 5.
22. Brown JR, Beebe GW, Kurtzke JR, et al: The design of clinical studies to assess therapeutic efficacy in multiple sclerosis. Neurology 1979;29:3-23.
23. Poser CW, Paty DW, Scheinberg L, et al: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227-231.
24. Efron B: Forcing a sequential design to be balanced. Biometrika 1971;58:403-417.
25. Kurtzke JF: Further notes on disability evaluation in multiple sclerosis with scale modifications. Neurology 1965;15:654-661.
26. Mora JS, Kao KP, Munsat TL: Indomethacin reduces the side effects of intrathecal interferon. N Engl J Med 1984;310:126-127.
27. Antel JP, Arnason BGW, Medof ME: Suppressor cell functions in multiple sclerosis: Correlation with clinical disease activity. Ann Neurol 1979;5:338-342.
28. Huddlestone JR, Oldstone MBA: T suppressor (Tg) lymphocytes fluctuate in parallel with changes in the clinical course of patients with multiple sclerosis. J Immunol 1979;123:1615-1618.
29. Kadish AS, Tansey FA, Yu GSM, et al: Interferon as a mediator of human lymphocyte suppression. J Exp Med 1980;151:637-650.
30. Onsrud M: Enhancement of suppressor cell generation in human mixed-lymphocyte cultures by interferon. Int Arch Allergy Appl Immunol 1982;67:315-321.
31. Aune TM, Pierce CW: Activation of a suppressor T-cell pathway by interferon. Proc Natl Acad Sci USA 1982;79:3808-3812.
32. Wong GHW, Bartlett PF, Clark-Lewis I, et al: Inducible expression of H-2 and la antigens on brain cells. Nature 1984;310:688-691.
33. Bukowski JF, Welsh RM: Interferon enhances the susceptibility of virus-infected fibroblasts to cytotoxic T cells. J Exp Med 1985;161:257-262.
34. Rose J, Salazar A: Characterization of the cerebrospinal fluid pleocytosis induced by intrathecal administration of beta-interferon. Ann Neurol 1986;20:166.
35. Panitch HS, Hirsh RL, Schindler J, et al: Immunological correlates of disease activity in MS patients treated with gamma interferon. Ann Neurol 1986;20:124.
36. Billiau A: Interferon therapy: Pharmacokinetic and pharmacological aspects. Arch Virol 1981;67:121-123.
37. Smith RA, Landel C, Cornelius CE, et al: Mapping the action of interferon on primate brain. J Interferon Res 1986;6(suppl 1):140.
38. Abreu SL: Suppression of experimental allergic encephalomyelitis by interferon. Immunol Invest 1982;11:1-7.
39. Abreu SL, Tondreau J, Levine S, et al: Inhibition of passive localized allergic encephalomyelitis by interferon. Int Arch Allergy Appl Immunol 1983;72:30-33.
40. Hertz F, Deghenghi R: Effect of rat and beta human interferon on hyperacute experimental allergic encephalomyelitis in rats. Agents Actions 1985;16:397-403.
41. McAlpine D, Lumsden CE, Acheson ED: Multiple Sclerosis: A Reappraisal. Baltimore, Williams & Wilkins, 1972, p 205.
42. Jacobs L, O'Malley JA, Freeman A, et al: Intrathecal interferon in the treatment of multiple sclerosis: Patient follow-up. Arch Neurol 1985;42:841-847.
43. Jacobs L, Salazar AM, Herndon R, et al: Intrathecal interferon in the treatment of multiple sclerosis, in Smith RA (ed): Interferons in the Treatment of Neurologic Disorders. New York, Marcel Dekker Inc, 1987.